



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

Myoblasts inhibit prostate cancer growth by paracrine secretion of TNF alpha

Stölting, Meline N L ; Ferrari, Stefano ; Handschin, Christoph ; Becskei, Attila ; Provenzano, Maurizio ;
Sulser, Tullio ; Eberli, Daniel

Abstract: PURPOSE: Myoblasts are capable of forming muscle fibers after transplantation and are therefore envisioned as a treatment for urinary incontinence after radical prostatectomy. However, the safety of this treatment and the interaction of myoblasts with remaining neighboring cancer are unknown. We investigated the interactions between myoblasts and prostate carcinoma cells in vitro and in vivo. **MATERIALS AND METHODS:** Myoblasts isolated from rectus abdominis were used in a series of co-culture experiments with prostate cancer cells and subcutaneously co-injected in vivo. Cell proliferation, cell cycle arrest and apoptosis of cancers in co-culture with myoblasts were assessed. Tumor volume and metastasis formation were evaluated in a mouse model. Tissue specific markers were assessed by immunohistochemistry, FACS analyses, Western blot and RT-qPCR. **RESULTS:** In this study we have demonstrated that myoblasts, in proximity to tumor, provide paracrine TNF to their microenvironment, decreasing tumor growth of all prostate cancer cell lines examined. Co-culture experiments showed induction of cell cycle arrest, tumor death by apoptosis and increased differentiation of myoblasts. This effect was largely blocked by TNF inhibition. The same outcome was demonstrated in a mouse model, where co-injected human myoblasts also inhibited tumor growth and metastasis formation of all prostate cancer cell lines evaluated. **CONCLUSIONS:** Myoblasts restrict prostate cancer growth and limit metastasis formation by paracrine TNF secretion in vitro and in vivo.

DOI: <https://doi.org/10.1016/j.juro.2012.10.071>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-68481>

Journal Article

Accepted Version

Originally published at:

Stölting, Meline N L; Ferrari, Stefano; Handschin, Christoph; Becskei, Attila; Provenzano, Maurizio; Sulser, Tullio; Eberli, Daniel (2013). Myoblasts inhibit prostate cancer growth by paracrine secretion of TNF alpha. *Journal of Urology*, 189(5):1952-1959.

DOI: <https://doi.org/10.1016/j.juro.2012.10.071>

Accepted Manuscript

Myoblasts inhibit prostate cancer growth by paracrine secretion of
TNF alpha

Meline N.L. Stölting, Stefano Ferrari, Christoph Handschin, Attila
Becskei, Maurizio Provenzano, Tullio Sulser, Daniel Eberli



PII: S0022-5347(12)05359-1
DOI: 10.1016/j.juro.2012.10.071
Reference: JURO 9580

To appear in: *The Journal of Urology*
Accepted date: 22 October 2012

Please cite this article as: Stölting, M.N.L., Ferrari, S., Handschin, C., Becskei, A., Provenzano, M., Sulser, T., Eberli, D., Myoblasts inhibit prostate cancer growth by paracrine secretion of TNF alpha, *The Journal of Urology*® (2012), doi: 10.1016/j.juro.2012.10.071.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

All articles printed in *The Journal of Urology*® are embargoed until 3 PM ET the day they are published as corrected proofs online. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

Title: **Myoblasts inhibit prostate cancer growth by paracrine secretion of TNF alpha**

Name of authors: **Meline N. L. Stölting¹, MD; Stefano Ferrari², PhD; Christoph Handschin³, PhD; Attila Becskei⁴, PhD; Maurizio Provenzano¹, MD. PhD; Tullio Sulser¹, Prof.; Daniel Eberli^{1*}, MD. PhD**

Name of institutions: ¹Laboratory for Urologic Tissue Engineering and Stem Cell Therapy, Division of Urology, University of Zurich, Frauenklinikstrasse 10, CH 8091 Zurich, Switzerland; ²Institute of Molecular Cancer Research, University of Zurich, Winterthurerstr 190, CH-8057 Zürich, Switzerland; ³Biozentrum, Focal Area Growth and Development, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland; ⁴Institute of Molecular Biology, University of Zurich, Winterthurerstr 190, CH-8057 Zürich, Switzerland

*Corresponding Author: Daniel.Eberli@usz.ch, Phone: +41 44 255 9619, Fax: +41 44 255 9620

Keywords: Prostate cancer, metastasis, autologous transplantation, Anticarcinogenic Agents, TNF-alpha

Word count (Abstract): 219

Word count (text): 2537

ABSTRACT

Purpose: Myoblasts are capable of forming muscle fibers after transplantation and are therefore envisioned as a treatment for urinary incontinence after radical prostatectomy. However, the safety of this treatment and the interaction of myoblasts with remaining neighboring cancer **are** unknown. We investigated the interactions between myoblasts and prostate carcinoma cells *in vitro* and *in vivo*.

Materials and Methods Myoblasts isolated from *rectus abdominis* were used in a series of co-culture experiments with prostate cancer cells and subcutaneously co-injected *in vivo*. Cell proliferation, cell cycle arrest and apoptosis of cancers in co-culture with myoblasts were assessed. Tumor volume and metastasis formation were evaluated in a mouse model. Tissue specific markers were assessed by immunohistochemistry, FACS analyses, Western blot and RT-qPCR.

Results: In this study we have demonstrated that myoblasts, in proximity to tumor, provide paracrine TNF α to their microenvironment, decreasing tumor growth of all prostate cancer cell lines examined. Co-culture experiments showed induction of cell cycle arrest, tumor death by apoptosis and increased differentiation of myoblasts. This effect was largely blocked by TNF α inhibition. The same outcome was demonstrated in a mouse model, where co-injected human myoblasts also inhibited tumor growth and metastasis formation of all prostate cancer cell lines evaluated.

Conclusions: Myoblasts restrict prostate cancer growth and limit metastasis formation by paracrine TNF α secretion *in vitro* and *in vivo*.

INTRODUCTION

Skeletal muscle comprises nearly 50% of the human body, is richly vascularized but rarely the site of cancer metastases. The cellular and molecular mechanisms underlying this phenomenon are not yet understood ¹. An intrinsic protective mechanism avoiding ingrowth of metastatic cells and formation of new tumors seems to exist. At the same time, skeletal muscles are the source of myoblasts ², which are capable of regenerating muscle fibers, and therefore are investigated for the treatment of several muscular dysfunctions, including stress urinary incontinence (SUI) ³, a common complication after radical prostatectomy ⁴. Preclinical studies have demonstrated that myoblasts, when implanted in the urinary sphincter, efficiently restore continence ⁵. The pelvic floor is also a frequent site of residual prostate cancer cells ⁶, but until now no investigations targeted cell fate and possible interactions between myoblasts and vicinal preexisting cancer.

Parallels have long been drawn between stem cells and cancer cells. In fact, both cell types share common features such as capacity for self-renewal, differentiation potential, relative quiescence, resistance to **drugs** and toxins, resistance to apoptosis, secretion of growth factors and stimulation of angiogenesis by production of vascular endothelial growth factor (VEGF) ⁷. These features could result in two possible outcomes: Cell proliferation or cell death. For instance, the presence of VEGF, which is secreted by many stem cells and progenitor cells including myoblasts ⁸, has the potential to promote prostate cancer angiogenesis leading to enhanced tumor growth and bone metastasis ⁹. On the other hand, myoblasts are activated by inflammation and use inflammatory cytokines to perform and regulate their cross-talk for activation and differentiation ². These same inflammatory cues, paracrine secreted by myoblasts, could **trigger** cancer apoptosis.

A recent study successfully demonstrated inhibition of melanoma cell growth in the presence of myoblasts, but failed to describe a possible intercellular mechanism that explains this cell behavior ¹⁰. Upon differentiation, myoblasts secrete tumor necrosis factor alpha (TNF α), which plays a key role in myoblast activation and differentiation, thereby linking inflammation to muscle regeneration ¹¹. In tumor cells, TNF α activates two parallel pathways, nuclear-factor- κ B (NF- κ B) or c-Jun N-terminal kinase (JNK). If NF- κ B is activated, TNF α acts as a growth promoter, stimulating proliferation and metastasis. However, if JNK is turned on, a Caspase3-dependent-apoptosis-pathway leads to cell death ¹². In this study, we demonstrate that myoblast-secreted-TNF α is capable of influencing vicinal prostate carcinoma by inducing cell cycle arrest and apoptosis *in vitro* and *in vivo*. Additionally, despite the proximity to prostate cancer, myoblasts will rapidly differentiate into well-organized myotubes. Cell-therapy with myoblasts might provide an ideal treatment of post-prostatectomy urinary incontinence by improving sphincter function and inhibiting potential recurrent prostate cancer growth in the pelvic floor.

MATERIAL AND METHODS

Cell Isolation and Culture

Upon ethical-approval and informed-consent, myoblasts were isolated from *rectus abdominis* biopsies of four male patients ($65 \pm 6.4y$) undergoing abdominal surgery. Biopsies were immediately processed according to established protocols¹³ and cells were expanded until passage 2 (P2) with a medium change every third day. Cell characterization was performed by FACS, Immunocytochemistry, RT-qPCR and Western Blot. Muscle tissue formation was assessed by injecting 5 million myoblasts with a collagen carrier (Collagen-type-I Rat tail,BD) into the subcutaneous space of nude-mice. Tissues were retrieved after three and six weeks for histological analysis. The three prostate carcinoma cell lines (ATCC-LGC Standard) were chosen according to their increasing clinical aggressiveness. They are retrieved from lymph node (LNCaP), bone (PC3), and brain (DU145) **metastases**. An aggressive vulvar **leiomyosarcoma** cell line (SK-LMS1) served as an additional cancer control. An indirect co-culture model (BD Falcon™) was applied, where cells shared culture medium (DMEM enriched with 10% fetal bovine serum (FBS) and 1% streptomycin/penicillin) thereby exchanging their cellular products without direct cell-cell-contact. Cancer cells were co-cultured with myoblasts of each patient for 10 **days** and analyses were performed at days 1, 4, 7 and 10. Myoblasts alone and cancer cell **line** cultures were used as control. **To maintain the total number of seeded cells in the single cell controls (myoblast or cancer alone), we have placed cells in both compartments, the culture dish and the insert.** All experiments were performed in triplicates and medium change was done every third day. $TNF\alpha$ was neutralized with a mouse monoclonal anti- $TNF\alpha$ antibody (Sigma,T-6817).

Growth Rate and Fiber Formation Assay (FFA)

In all cases, triplicate samples of log phase cells were plated at a density of 5×10^3 cells/cm². Cell number and viability was confirmed after trypsinisation by toluidine blue staining (**n=36**). The formation of myofibers was examined on slide chambers and, after 8 days in differentiating condition myofibers were fixed (methanol, 7min), stained (1:20 Giemsa, 1h) and air dried. Images were taken with a Leica-Imager-M1 Microscope. **Five high-power-fields (HPF) per sample were analyzed (n=30) and results were expressed as differentiation rate, which was calculated by the number of nuclei in differentiated myofibers/HPF divided by the total number of nuclei/HPF.**

Western Blot

Cells were washed with PBS/protease inhibitor (Sigma) and lysed with lysis buffer (50mM Tris-HCl, 150mM NaCl, 10% glycerol, 1% Triton X-100, 2mM EDTA, 40mM β -glycerophosphate, 50mM sodium-fluoride, 10 μ g/ml leupeptin, 10 μ g/ml aprotinin, 1 μ M pepstatinA, 1mM PMSF). Samples were centrifuged (10min, 13000rpm), and proteins determined in the supernatant. Culture medium proteins were concentrated by filtering through a 10kDa filter (Amicon Ultra, Millipore). Total protein was measured using DC™ Protein-Assay (Bio-Rad), and 30 μ g of protein lysate was loaded on 12% Biorad gels. Proteins were transferred onto PVDF-membranes (Millipore), blocked (1h, 5% non-fat-dry-milk), and incubated (4°C, overnight) with anti-Desmin (1:100, BD Biosciences), anti-MyH (1:6, DSHB), anti-TNF α (1:500, Sigma), anti-p21^{WAF1} (1:1000, Calbiochem), Cleaved Caspase-3-Asp175 (1:1000, Cell- Signaling) and anti-GAPDH (1:2000, Sigma). Membranes were washed, incubated with HRP-conjugated

secondary antibody and developed by ECL-technique (ECL-Kit,Amersham).

RT-qPCR

RNA extraction, cDNA preparation and RT-qPCR reactions were done using Taqman® gene expression assay kits (Applied Biosystems), according to manufacturer's protocols. Data were normalized with 18S expression, quantitatively analyzed by quantification cycles (C_q) and fold changes and graphically represented in amplification plots. MIQE guidelines were followed.

In vivo Experiments and Tumor Size Determination

Myoblasts and tumor cells were cultured as described above, mixed with a collagen carrier (1mg/ml) and bilaterally injected into the dorsal subcutaneous space of 8 nude-mice (n=16 samples) per group. Cell-cell interactions *in vivo* were examined on day 21 and 42 after injection using nine groups: Myoblast (5×10^6) alone and co-injected with each of the four cancer cell lines (LNCaP, PC3, DU145 and SK-LMS, 2.5×10^6) and the four tumors alone (2.5×10^6).

The experiments were performed in triplicates and repeated four times with myoblasts from 4 different patients. Tumor volume and growth was measured ($\text{mm}^3 = a^2 \times b / 2$). Animals were sacrificed by CO₂ asphyxiation. Tumor/sample size, myoblast differentiation, tumor aggressiveness and metastasis (lymph node, lung and liver) were assessed after 21 and 42 days by histological staining.

Histological Staining and Immunocytochemistry

Cells/tissues were fixed (4% PFA), permeabilized (0,5% Triton), blocked (5% BSA/0,1% Triton) and immunolabelled with anti-Pax7 (1:200,Sigma), anti-MyoD (1:100,BDPharmingen), anti-Desmin (1:50,BDBiosciences), anti-MyH (1:4,DSHB)

and anti-sarcomeric actinin (1:1000, Sigma), and incubated for 1 hour with anti-mouse-IgG-Cy3 (Sigma). Digital images were taken with a Leica Imager M1 Microscope. Tissues were also stained with hematoxylin and eosin (HE). Histomorphometric analysis was performed using "IMAGEJ for microscopy".

Statistics

Presented data are expressed as averages with corresponding standard deviation. Analyses by independent samples t-tests, one way ANOVA **with Bonferroni post hoc analysis** or Pearson Correlation were done with SPSS v20 (SPSS Inc, Chicago, IL). A $p < 0.05$ was considered significant.

RESULTS

Cancer cells undergo cell cycle arrest and apoptosis in co-culture with myoblasts *in vitro*

Human myoblasts were successfully isolated and characterized by FACS, Immunocytochemistry (ICC) and Fiber Formation Assay (FFA). The cell population expressed $76.5 \pm 2.3\%$ PAX-7, $60.6 \pm 6.3\%$ MyOD, and $81.6 \pm 2.5\%$ desmin. After 10 days in co-culture cancer cell lines significantly decreased ($p < 0.001$) their growth by $87.9 \pm 0.3\%$ for DU145, $66.0 \pm 0.1\%$ for LNCaP, $33.6 \pm 6.7\%$ for PC3, and $42.0 \pm 0.6\%$ for SK-LMS1 (Figure 1A, 1B, 1C). The decrease in cancer cell growth was due to apoptosis and cell cycle arrest, as demonstrated by RT-qPCR and Western Blot (Figure 1D). LNCaP and PC3 showed a >9 fold increase of mRNA for Caspase 3 and p21^{WAF} when grown in co-culture, while DU145 and SK-LMS showed a lower but still significant increase. Western Blot confirmed these data.

Myoblasts in co-culture with cancer cells (Figure 1E, 1F) displayed a decreased growth rate as well (Figure 1G), they fused and developed muscle fibers (Figure 1H, $p < 0.001$). While only $4.2 \pm 1.0\%$ of the control myoblasts formed muscle fibers, the differentiation ratio of myoblasts increased in parallel to the respective prostate cancer line aggressiveness ($p = 0.011$), with rates of $11.5 \pm 5.5\%$ in LNCaP, $14.5 \pm 6.9\%$ in PC3 and $25.3 \pm 2.3\%$ in DU145.

TNF α -dependent induction of cell cycle arrest and apoptosis in cancer cell lines co-cultured with myoblasts.

Myoblasts demonstrated a striking, up to 25 fold, increase of TNF α mRNA when exposed to tumor (Figure 2A). This led to significantly higher amounts of TNF α protein ($p < 0.001$) in the medium in the co-culture system (Figure 2B). **The relative protein expression levels measured in the culture medium were 0.92 ± 0.13 for**

myoblast control and 3.01 ± 0.17 for LNCaP, 4.71 ± 0.26 for PC3, 5.88 ± 0.26 for DU145 and 5.15 ± 0.33 for SK-LMS co-cultures. These myoblast-TNF α -secretion values increased gradually according to the corresponding prostate carcinoma aggressiveness ($p < 0.001$), significantly correlating (Pearson: 0.754, $p < 0.001$) with the myoblast differentiation ratio (Figure 2C). **The TNF α concentration in culture medium also negatively correlated to cancer cell growth ($p < 0.001$, Pearson value -0.58) suggesting that myoblast-paracrine-TNF α is sufficient to induce significant cancer growth inhibition. A parallel assay demonstrated that cancer cell lines alone do not reach detectable levels of TNF α mRNA or protein expression.**

TNF α -antibody blocking in co-culture permitted cancer re-growth at day 10 to $84.0 \pm 0.3\%$ for LNCaP, $99.1 \pm 11.4\%$ for PC3, $23.3 \pm 0.3\%$ for DU145 and $82.2 \pm 1.4\%$ for SK-LMS1 (Figure 2D) of control **values (=100%)**. Using TNF α blocking in co-culture also decreased the myoblast differentiation ratio by reducing Caspase3 and p21^{WAF} mRNA and protein expression to control-levels (Figure 2E).

Myoblasts restrain tumor growth inducing cancer apoptosis and cell cycle arrest *in vivo*

Interactions between myoblasts and prostate cancer were further investigated *in vivo* by co-injecting myoblasts and tumor cells subcutaneously in nude-mice (Figure 3A). All co-injected samples showed a significantly reduced tumor growth after 21 and 42 days (Figure 3A, 3B. $p < 0.05$). Despite rigorous mixing before injection, muscle and cancer grew in distinct clusters of each cell type (Figure 4). **Immunohistochemistry** was able to confirm the higher level of Caspase 3 and p21^{WAF} expression in all co-injected cancer samples.

Lymph node micrometastases (Figure 3C, **3D**) were significantly reduced in co-injected groups (10.9%), when compared to control (90.6%, $p < 0.001$). No metastases to lung and liver were detected. The extent to which myoblasts influenced cancer growth was again proportional to cancer aggressiveness (Figure 4). Histomorphometric distance analyses demonstrated that the tumor areas closer to the newly formed muscle underwent apoptosis and cell cycle arrest more intensely (Pearson: -0.91 and -0.86 respectively) supporting the hypothesis that soluble factors are responsible for the antitumor effects (Figure 5). Despite the evident changes in tumor behavior, muscle tissue developed a well-organized and differentiated structure *in vivo*. We could not detect any changes in muscle phenotype in the presence of tumor, which also preserved a similar expression of Desmin and p21^{WAF}.

DISCUSSION

Cell-cell interactions play a crucial role in tissue formation, regeneration processes and inflammatory reactions. Cellular signaling between neighboring cells is based on two main mechanisms: Growth modulation by endogenous secretion of active compounds and cell competition. These two mechanisms have been well documented in fibroblasts, which are capable of secreting growth factors and other peptides, thus delivering cues to neighboring cells. Fibroblasts isolated from breast tumor areas are permissive allowing breast cancer metastasis, whereas fibroblasts from normal breast tissue restrict tumor growth¹⁴. Cell competition has also been proposed to regulate early cancer stages, when developing cancer cells overcome genomic constraints¹⁵. It triggers apoptosis within and around tumors by promoting rivalry between different anaplastic and normal cell lineages¹⁵.

We have demonstrated that myoblasts in co-culture with cancer cells significantly increase TNF α -secretion *in vitro* and *in vivo*. TNF α has been isolated and described 30 years ago, and its clinical application in cancer therapy has been studied ever since¹⁶. Due to its systemic toxicity, TNF α is clinically only recommended in the treatment of advanced neoplasia, including sarcoma and melanoma, and in advanced cases, when limb amputation would represent the next step¹⁷. Myoblasts are known to secrete higher TNF α levels when differentiating¹⁸ and this paracrine-secretion evokes microenvironmental changes, which control muscle regeneration by activating Pax7 in quiescent myoblasts and thereby induce differentiation and muscle formation¹¹.

In our study myoblast-secreted-TNF α levels increase according to tumor aggressiveness, in accordance with previous findings correlating prostate cancer Gleason-score and inflammatory response to endogenous cytokines¹⁹. The presence of inflammatory factors related to muscle regeneration plays a role in

myoblast-secreted-TNF α regulation¹¹. This leads to the hypothesis that specific inflammatory cues delivered by the prostate tumor stimulate neighboring myoblasts to produce higher TNF α levels. A potential pathway is the increase of TACE production due to stress and nutrient shortage, leading to increased release of endogenous TNF α by muscle cells²⁰.

To investigate the paracrine influences we used a co-culture system where myoblast and cancer cells share the same environment without cell-cell-contact. All cancer cell lines in co-culture showed a significant decrease in growth and increase in apoptosis and cell cycle arrest. This inhibitory effect was almost completely blocked when TNF α was antagonized. In cancer cells TNF α binds to TNFR-1 receptor and triggers Caspase-3 activation leading to an apoptotic cascade and cell death¹⁶. The dual effect of TNF α inducing differentiation in myoblasts and apoptosis in tumors can be explained by two parallel pathways: activation of p38 α and c-Jun N-terminal kinase (JNK). Once p38 α is activated, Pax7 initiates myogenesis and myoblast differentiation¹¹ and, by activating the JNK pathway, triggers cancer apoptosis through a Caspase-3-dependent pathway¹². A further line of action of TNF α in cancer inhibition affects tumor vascularity, probably due to higher response to TNF α in tumoral vessels by receptor up-regulation (TNFR-1)¹⁶.

Our findings demonstrate that co-injected myoblasts are able to limit cancer growth *in vivo*, again significantly triggering a cell cycle arrest and apoptosis in the cancer tissue. The histomorphometric distance analysis confirmed the role of a soluble factor in hindering tumor growth, supporting that TNF α might be a key player. Further, a significant reduction of lymph node metastasis formation was shown after co-injection, indicating an effect on confining the cancer to the primary site. We anticipate that investigations targeting cancer-mediated-stress factors on muscle

cells **as well as the additional effects of physical cell-cell and cell-ECM**

(extracellular matrix) interactions will be the focus of future efforts towards a better understanding of interactions between cancer and Adult Stem Cells, such as myoblasts.

This research was based on established models for cancer research, however the complex interactions between stromal and tumor cells were not addressed. We used human myoblasts and cancer cell lines in an animal model. In order to avoid xenograft rejection nude mice with limited immune response were used.

CONCLUSIONS

Myoblasts can be isolated from patients' muscle biopsies, rapidly grown in culture, implanted and thereafter form functional muscle within weeks. Our results indicate that differentiating myoblasts secrete TNF α , which induces apoptosis and cell cycle arrest in prostate cancer. These characteristics make myoblasts a promising cell source for muscle reconstruction, even in the proximity of cancer.

REFERENCES

1. Plaza, J. A., Perez-Montiel, D., Mayerson, J., et al. Metastases to soft tissue. *Cancer*, **112**: 193, 2008
2. Gopinath, S. D., Rando, T. A.. Stem Cell Review Series: Aging of the skeletal muscle stem cell niche. *Aging Cell*, **7**: 590, 2008
3. Carr, L., Steele, D., Steele, S., et al.. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. *Int Urogynecol J*, **19**: 881, 2008
4. Klingler, H. C., Marberger, M.. Incontinence after radical prostatectomy: surgical treatment options. *Curr Opin Urol*, **16**: 60, 2006
5. Eberli, D., Aboushwareb, T., Soker, S., et al.. Muscle Precursor Cells for the Restoration of Irreversibly Damaged Sphincter Function. *Cell Transplant*, 2012
6. Leventis, A. K., Shariat, S. F., Slawin, K. M.. Local Recurrence after Radical Prostatectomy: Correlation of US Features with Prostatic Fossa Biopsy Findings¹. *Radiology*, **219**: 432, 2001
7. Reya, T., Morrison, S. J., Clarke, M. F., et al.. Stem cells, cancer, and cancer stem cells. *Nature*, **414**: 105, 2001
8. Mac Gabhann, F., Ji, J. W., Popel, A. S.. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. *J Appl Physiol*, **102**: 722, 2007
9. Carducci, M. A., Jimeno, A.. Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists. *Clin Cancer Res*, **12**: 6296s, 2006
10. Parlakian, A., Gomaa, I., Solly, S., et al.. Skeletal Muscle Phenotypically Converts and Selectively Inhibits Metastatic Cells in Mice. *PLoS ONE*, **5**: e9299, 2010
11. Palacios, D., Mozzetta, C., Consalvi, S., et al.. TNF/p38[alpha]/Polycomb Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle Regeneration. *Cell stem cell*, **7**: 455, 2010
12. Wang, X., Lin, Y.. Tumor necrosis factor and cancer, buddies or foes[quest]. *Acta Pharmacol Sin*, **29**: 1275, 2008
13. Eberli, D., Soker, S., Atala, A., et al.. Optimization of human skeletal muscle precursor cell culture and myofiber formation in vitro. *Methods*, **47**: 98, 2009
14. Dong-LeBourhis, X., Berthois, Y., Millot, G., et al.. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. *Int J Cancer*, **71**: 42 1997
15. Moreno, E.. Is cell competition relevant to cancer? *Nat Rev Cancer*, **8**: 141, 2008
16. van Horssen, R., ten Hagen, T. L. M., Eggermont, A. M. M.. TNFalpha in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. *Oncologist*, **11**: 397, 2006
17. Taeger, G., Grabellus, F., Podleska, L. E., et al.. Effectiveness of regional chemotherapy with TNF-alpha/Melphalan in advanced soft tissue sarcoma of the extremities. *Int J Hyperthermia*, **24**: 193, 2008
18. Chen, S.-E., Gerken, E., Zhang, Y., et al.. Role of TNFalpha signaling in regeneration of cardiotoxin-injured muscle. *Am J Physiol Cell Physiol*, **289**: C1179, 2005
19. Nuñez, C., Cansino, J. R., Bethencourt, F., et al.. TNF/IL-1/NIK/NF-kappaB transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). *Histopathology*, **53**: 166, 2008

20. Zhan, M., Jin, B., Chen, S.-E., et al.. TACE release of TNF α mediates mechanotransduction-induced activation of p38 MAPK and myogenesis. *J Cell Sci*, **120**: 692, 2007

FIGURE LEGENDS

Figure 1 – **Co-culture effects on myoblasts and cancer cells.** Cell growth rate, differentiation ratio, morphology and gene expression were influenced by co-culture. Prostate carcinoma and sarcoma cells significantly decreased in growth (A, B, E) and underwent apoptosis and/or cell cycle arrest (B, G). **Activation of the apoptotic pathway was determined by staining for cleaved Caspase-3 (Asp175). A positive staining was found in DU145 cells in co-culture with myoblasts (A) but not in control of tumor alone (B).** Desmin staining in co-culture (C) and control (D) demonstrated an evident differentiation of myoblasts into well-organized myotubes. Cytoskeleton labelled in green (Phalloidin 488) and secondary antibody in red (Cy3). Caspase 3 and p21 mRNA fold increase and protein expression (G) significantly increased when compared to tumor control (dashed line=1.0). Myoblasts differentiated rapidly in the presence of tumor, significantly increasing differentiation ratio and, consequently, decreasing cell growth (F, H). Samples in co-culture with myoblast were represented as (+ Mb) and control without myoblasts as (- Mb). mRNA fold increase was normalized with 18S reference gene (*p<0.05, **p<0.001).

Figure 2 – **Myoblast secreted TNF α induce myoblast differentiation and inhibit cancer cell line growth rate by inducing apoptosis and cell cycle arrest.** (A) RT-qPCR assay demonstrates that myoblast TNF α mRNA expression is increased after 4 days of co-culture with different cancer cell lines. A significant difference could be found between different prostate cancer cell lines, increasing according to tumor aggressiveness. (B) Myoblasts TNF α secretion increases according to the cancer aggressiveness in co-culture. CM: Culture Medium. (C) Myoblast differentiation ratio

correlate (Pearson correlation: 0.754) to the amount of produced $\text{TNF}\alpha$. (D) Cell growth rate of cancer (LNCaP, PC3, DU145 and SK-LMS-1) was assessed by cell counting at day 1, 4, 7 and 10 of co-culture. All cancer cell lines showed a significant decrease in growth in the presence of myoblasts (bold lines), when compared to control (fine line). Cancer growth rate was in great part recovered (dashed lines) after $\text{TNF}\alpha$ neutralization. (E) Apoptosis and cell cycle arrest are triggered in all cancer cells co-cultured with myoblasts. Again $\text{TNF}\alpha$ blocking reversed in great part these effects. Caspase 3 and p21 tumor control mRNA fold increase is represented with a dashed line (=1.0). * $p < 0.05$, ** $p < 0.001$

Figure 3 – Tumor growth and lymph node metastasis was reduced *in vivo* in samples co-injected with myoblasts. (A) 21 days after subcutaneous cell injection, tumor size was measured and a significant tumor size difference was found between co-injected and control samples. On day 42, myoblast co-injected tumor mass shrank, whereas control samples kept growing. (B) Final tumor size at day 42 was significantly smaller in myoblast co-injected samples. (C) Axillar lymph node metastasis assessment was performed by analysis of metastasis with H&E, Desmin and cytokeratin staining, positive lymph nodes. Ln ratio of axillar metastasis was also significantly reduced ($p < 0.001$) in all tested cancers, when co-injected with myoblasts. **(D) Pan-cytokeratin staining of mice axillar lymph node 3 weeks after subcutaneous injection of LNCaP with and without myoblasts.** Samples co-injected with myoblasts were represented as (+ Mb) and control without myoblasts as (- Mb). * $p < 0.05$, ** $p < 0.001$

Figure 4 – Histological analysis of tumor formation *in vivo*. At day 42, HE staining demonstrates a tendency of newly formed muscle and cancer tissue (first row) to

growth in clusters, with differentiated muscle areas impairing growth of neighbor tumor masses. In opposition, control cancers (second row) grow freely forming bigger and complex tumor masses. Increasing Caspase3 and p21^{WAF} expression was detected in all tumors in samples co-injected with myoblasts (third and fifth row). Co-injected myoblasts differentiated into p21^{WAF} positive muscle fibers. Samples co-injected with myoblasts were represented as (+ Mb) and controls are cancer cell lines injected without myoblasts (-Mb). In the co-injected samples muscle is represented with a “M” and cancer tissue areas with a “C”. DAPI (blue), anti-mouse IgG Cy3 (red), and the injected myoblasts were labeled *in vitro* with PKH 67 (green).

Figure 5 – Histomorphometric analyses of co-injected tumor with myoblasts.

Histomorphometric analysis demonstrates a significant increase on apoptosis (A) and cell cycle arrest (B) in all co-injected tumors. (C) Three tumor areas were analyzed according to distance of newly formed muscle. The total positive area, calculated by fluorescence intensity, demonstrated a gradient of Caspase 3 and p21 expression in all cancers tested. These directly correlated with the proximity to differentiating muscle tissue. Samples co-injected with myoblast were represented as (+ Mb) and control without myoblasts as (- Mb). *p<0.05, **p<0.001

Key of Definitions for Abbreviations

TNF α – Tumor Necrosis Factor alpha
FACS – Fluorescence-activated cell sorting
WB – Western Blot
RT-qPCR – real time quantitative polymerase chain reaction
SUI – stress urinary incontinence
VEGF – vascular endothelial growth factor
NF- κ B – nuclear-factor- κ B
JNK – c-Jun N-terminal kinase
FBS – fetal bovine serum
FFA - Fiber Formation Assay
HPF – high-power-fields
PFA – Paraformaldehyde
HE – Hematoxylin and eosin
ICC – Immunocytochemistry
p21^{WAF} – Cyclin-dependent kinase inhibitor 1A
TNFR-1 – Tumor Necrosis Factor receptor 1
Pax7 – Paired box protein 7
MyoD – Myogenic Differentiation

Figure1

[Click here to download high resolution image](#)




Figure2

[Click here to download high resolution image](#)




Figure3

[Click here to download high resolution image](#)